Stock NEXI NEXIMMUNE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials NexImmune, Inc.

Equities

NEXI

US65344D2080

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
3.37 USD -1.17% Intraday chart for NexImmune, Inc. -3.44% +51.80%
Apr. 17 North American Morning Briefing : Stock Futures -2- DJ
Apr. 16 NexImmune, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2021 2022 2023
Capitalization 1 104.7 6.34 2.349
Enterprise Value (EV) 1 22.88 -27.28 -0.7846
P/E ratio -1.81 x -0.09 x -0.07 x
Yield - - -
Capitalization / Revenue - - -
EV / Revenue - - -
EV / EBITDA -0.44 x 0.44 x 0.03 x
EV / FCF -755,087 x 922,731 x 43,831 x
FCF Yield -0% 0% 0%
Price to Book 1.26 x 0.2 x 0.67 x
Nbr of stocks (in thousands) 908 1,043 1,058
Reference price 2 115.2 6.078 2.220
Announcement Date 3/9/22 3/28/23 4/16/24
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales - - - - - -
EBITDA 1 -13.04 -20.45 -27.23 -52.39 -62.09 -28.16
EBIT 1 -13.24 -20.89 -27.85 -53.26 -63.08 -29.18
Operating Margin - - - - - -
Earnings before Tax (EBT) 1 -12.83 -20.55 -29.87 -50.9 -62.51 -32.34
Net income 1 -12.83 -20.55 -29.87 -50.9 -62.51 -32.34
Net margin - - - - - -
EPS 2 -332.0 -467.7 -660.4 -63.51 -64.95 -30.82
Free Cash Flow - -12.96 -15.92 -30.3 -29.56 -17.9
FCF margin - - - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 1/19/21 1/19/21 3/31/21 3/9/22 3/28/23 4/16/24
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2
Net sales 1 - - - - - - - -
EBITDA - - - - - - - -
EBIT 1 -15.49 -15.53 -15.05 -15.93 -14.86 -17.25 -9.825 -7.785
Operating Margin - - - - - - - -
Earnings before Tax (EBT) 1 -14.65 -15.53 -15.02 -15.86 -14.73 -16.89 -9.565 -7.566
Net income 1 -14.65 -15.53 -15.02 -15.86 -14.73 -16.89 -9.565 -7.566
Net margin - - - - - - - -
EPS 2 -16.25 -17.25 -16.50 -17.25 -15.00 -16.25 -9.250 -7.250
Dividend per Share - - - - - - - -
Announcement Date 11/12/21 3/9/22 5/12/22 8/15/22 11/14/22 3/28/23 5/15/23 8/10/23
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - 14.9 - - -
Net Cash position 1 12.1 10.1 - 81.8 33.6 3.13
Leverage (Debt/EBITDA) - - -0.5487 x - - -
Free Cash Flow - -13 -15.9 -30.3 -29.6 -17.9
ROE (net income / shareholders' equity) - -192% 1,161% -150% -108% -181%
ROA (Net income/ Total Assets) - -93.7% -139% -65.1% -58.8% -70.6%
Assets 1 - 21.93 21.46 78.25 106.3 45.8
Book Value Per Share 2 -540.0 -857.0 -1,380 91.70 31.00 3.290
Cash Flow per Share 2 9.490 182.0 100.0 33.20 33.20 3.000
Capex 1 0.94 1.25 0.86 2.35 1.26 0.05
Capex / Sales - - - - - -
Announcement Date 1/19/21 1/19/21 3/31/21 3/9/22 3/28/23 4/16/24
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
NEXIMMUNE, INC. Stock NexImmune, Inc.
+51.80% 4.62M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. NEXI Stock
  4. Financials NexImmune, Inc.